FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

By Eddie Staley
Benzinga Staff Writer
October 05, 2011 7:35 AM

Merck (NYSE: MRK) and ARIAD Pharmaceuticals, Inc., (NASDAQ: ARIA [FREE Stock Trend Analysis]), today announced that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy. 

The FDA assigned a Standard review classification to this application.

Benzinga's real-time audio news gives you the fastest alerts possible on market-moving events. Sign up for a free trial today!

 

Notícia em Benzinga

http://www.benzinga.com/news/11/10/1965969/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-in
Acesso em 08 de outubro de 2011.